Physiological roles of the GIP receptor in murine brown adipose tissue
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Objective Glucose-dependent insulinotropic polypeptide (GIP) is secreted from the gut in response to nutrient ingestion and promotes meal-dependent insulin secretion and lipid metabolism . Loss or attenuation of GIP receptor (GIPR) action leads to resistance to diet-induced obesity through incompletely understood mechanisms. The GIPR is expressed in white adipose tissue ; however, its putative role in brown adipose tissue (BAT) has not been explored. Methods We investigated the role of the GIPR in BAT cells in vitro and in BAT-specific ( Gipr BAT−/− ) knockout mice with selective elimination of the Gipr within the Myf5 + expression domain. We analyzed body weight , adiposity , glucose homeostasis , insulin and lipid tolerance, energy expenditure, food intake , body temperature, and iBAT oxygen consumption ex vivo . High-fat diet (HFD)-fed Gipr BAT−/− mice were studied at room temperature (21 °C), 4 °C, and 30 °C ambient temperatures. Results The mouse Gipr gene is expressed in BAT, and GIP directly increased Il6 mRNA and IL-6 secretion in BAT cells . Additionally, levels of thermogenic, lipid and inflammation mRNA transcripts were altered in BAT cells transfected with Gipr siRNA . Body weight gain , energy expenditure, and glucose and insulin tolerance were normal in HFD-fed Gipr BAT−/− mice housed at room temperature. However, Gipr BAT−/− mice exhibited higher body temperatures during an acute cold challenge and a lower respiratory exchange ratio and impaired lipid tolerance at 21 °C. In contrast, body weight was lower and iBAT oxygen consumption was higher in HFD-fed mice housed at 4 °C but not at 30 °C. Conclusions The BAT GIPR is linked to the control of metabolic gene expression, fuel utilization, and oxygen consumption. However, the selective loss of the GIPR within BAT is insufficient to recapitulate the findings of decreased weight gain and resistance to obesity arising in experimental models with systemic disruption of GIP action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 5×
“Indeed, these findings have been achieved with a broad number of experimental approaches, including genetic inactivation of the GIP receptor (Gipr) [8], disruption of the Gip gene in mice [9], as well as GIPR blockade using receptor antagonists, or immunoneutralization of the GIP peptide in mice, rats, and non-human p…”
BackgroundInfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Moreover, tirzepatide, an acylated GIPR-GLP-1R co-agonist, produced more weight loss than semaglutide and decreased fat mass, reduced food intake, and enhanced energy expenditure in mice with diet-induced obesity [23].”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 2×
“Notably, several GIPR co-agonists reduced fat mass, decreased body weight and improved glucose control in non-human primates [21] and in human subjects with type 2 diabetes [21,22].”
BackgroundResultSelf-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 2×
“Whole body Gipr / mice maintain a higher body temperature in the cold and exhibit greater non-shivering thermogenic responses Global loss of Gipr in mice is associated with resistance to diet-induced obesity [8,15,16,19], however the relative contributions of reduced food intake and/or increased energy expenditure to…”
BackgroundMethodDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418 · cited 4×
“GLP-1 controls appetite, attenuates gut motility, decreases chylomicron secretion, promotes natriuresis, and attenuates inflammation, actions mediated through the GLP-1 receptor (GLP-1R) [3].”
BackgroundInfluentialSelf-citationHøjberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“Notably, several GIPR co-agonists reduced fat mass, decreased body weight and improved glucose control in non-human primates [21] and in human subjects with type 2 diabetes [21,22].”
Background
Cited by
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Studies in mice link GIPR signalling using mono-agonists or tirzepatide to reduced food intake and robust activation of BAT 52,53 .”
InfluentialSelf-citationCampbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Self-citationRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“No difference in body weight is seen between wt mice and mice that lack Gipr in the brown adipose tissue (BAT) (180) or the pancreatic b-cells (181).”
Background
Metadata
- Authors
- Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 28
- Pages
- 14-25
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2968930759
- Cited by
- 70
- References
- 24
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiological roles of the GIP receptor in murine brown adipose tissue. https://app.cochat.ai/papers/10.1016/j.molmet.2019.08.006
- The paper
- Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019). Physiological roles of the GIP receptor in murine brown adipose tissue. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2019.08.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.